Familial Amyloid Polyneuropathy Market Outlook Highlights The Next Major Growth Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Familial Amyloid Polyneuropathy Market Expected To Reach $2.42 Billion By 2030 At 8% CAGR
The market for familial amyloid polyneuropathy has experienced notable expansion over the past few years, with projections indicating a rise from $1.65 billion in 2025 to $1.79 billion in 2026, reflecting a compound annual growth rate of 8.3%. This upward trajectory in the historical phase was driven by factors such as the diagnosis of rare diseases, increased awareness of genetic disorders, progress in transplant medicine, advancements in neurology research, and the growing adoption of supportive care approaches.
The familial amyloid polyneuropathy market is projected to achieve substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $2.43 billion, reflecting a compound annual growth rate (CAGR) of 8.0%. This projected growth during the forecast period is driven by advancements in gene therapy, the implementation of early genetic testing, increased financial support for rare disease research, the integration of precision medicine, and the expansion of specialty pharmacy services. Key developments shaping this period include the broader uptake of TTR stabilizers, the increasing utilization of gene silencing treatments, a rise in genetic screening protocols, heightened attention toward managing rare diseases, and the establishment of more specialized healthcare facilities.
Download A Free Sample Report For Comprehensive Market Insights:
Familial Amyloid Polyneuropathy Market Growth Drivers And Industry Catalysts
The increasing emphasis on gene therapy is anticipated to drive forward the expansion of the familial amyloid polyneuropathy market. This therapeutic approach works by altering or replacing defective genes to tackle the fundamental cause of diseases. Gene therapy is gaining traction because it directly targets and corrects faulty genes, delivering long-term or permanent solutions instead of merely alleviating symptoms. In the context of familial amyloid polyneuropathy, gene therapy aims to rectify or silence the faulty transthyretin (TTR) gene, thereby preventing the formation of damaging amyloid proteins. This action reduces amyloid deposits, slows the progression of the disease, and helps maintain nerve functionality. For example, data from July 2023, as reported by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based drug and device provider, showed that 247 gene therapies were in Phase II at the end of the first quarter; this figure increased by 5% to 260 by the conclusion of the second quarter. Consequently, the growing focus on gene therapy is fueling the growth of the familial amyloid polyneuropathy market.
Familial Amyloid Polyneuropathy Market Segment Performance And Strategic Opportunities
The familial amyloid polyneuropathy market covered in this report is segmented –
1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment
2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis
3) By Patient Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran
2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy
3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling
4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants
5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment
Familial Amyloid Polyneuropathy Market Trends Influencing Long-Term Demand
Major players in the familial amyloid polyneuropathy market are prioritizing the creation of cutting-edge therapeutic options, including RNA interference (RNAi) treatments, aimed at decelerating illness progression and enhancing patient well-being. RNA interference (RNAi) therapies represent sophisticated interventions that silence genes responsible for disease by focusing on their messenger RNA (mRNA), thereby halting the generation of harmful proteins and tackling genetic disorders at their fundamental level. To illustrate, Alnylam Pharmaceuticals, a biopharmaceutical firm based in the United States, introduced AMVUTTRA (vutrisiran) in March 2025, after receiving approval from the Food and Drug Administration (FDA) for managing cardiomyopathy resulting from wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This treatment, administered as four subcutaneous doses annually, is crafted to address both ATTR-CM and the polyneuropathy linked to hereditary transthyretin-mediated amyloidosis (hATTR-PN). By lowering the production of the transthyretin (TTR) protein, which is the underlying cause of the condition, it substantially reduces cardiovascular mortality, hospital admissions, and urgent heart failure visits, as evidenced by the findings from the HELIOS-B Phase 3 clinical trial.
Familial Amyloid Polyneuropathy Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Precision BioSciences Inc., Creative Biolabs, Stanford Health Care, Duke University Health System, YolTech Therapeutics
Access The Complete Familial Amyloid Polyneuropathy Market Report:
Familial Amyloid Polyneuropathy Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the familial amyloid polyneuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
